ProQR Therapeutics
PRQR
64 hedge funds and large institutions have $286M invested in ProQR Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 6 closing their positions.
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
158% more capital invested
Capital invested by funds: $111M → $286M (+$175M)
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
39% more funds holding
Funds holding: 46 → 64 (+18)
33.6% more ownership
Funds ownership: 52.68% → 86.28% (+34%)
21% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $2.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.8M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.8M |
| 4 |
Citigroup
New York
|
+$9.63M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$5.02M |
| 2 |
Morgan Stanley
New York
|
-$2.73M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.95M |
| 4 |
Renaissance Technologies
New York
|
-$1.41M |
| 5 |
Millennium Management
New York
|
-$741K |
PRQR Hedge Fund Activity: Q1 2021 in Review
64 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2021, worth a combined $286M — up 158% from $111M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRQR positions and 6 closed out — a net gain of 18 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.8M. The largest seller was Artal Group, exiting entirely with an estimated $5.02M sold.
- 64 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2021, up from 46 in Q4 2020.
- Funds reported $286M of ProQR Therapeutics stock for Q1 2021, up 158% quarter-over-quarter.
- 24 funds opened new ProQR Therapeutics positions in Q1 2021 and 6 closed out, a net change of +18 holders.
- The largest ProQR Therapeutics buyer in Q1 2021 was Fidelity Investments, an estimated $23.8M added.
- The largest ProQR Therapeutics seller in Q1 2021 was Artal Group, an estimated $5.02M sold.
Based on aggregated 13F filings for Q1 2021.